Private company

Adhera Therapeutics, Inc.

Adhera Therapeutics, Inc. is an American pharmaceutical preparations company based in Los Angeles.²

Last updated Oct 21, 2026.

Overview

IndustryPharmaceutical Preparations²
HeadquartersLos Angeles, United States²
Incorporated inDE³
Business addressP.O. Box 2161, Wake Forest, Nc 27588³
Filer categoryNon-accelerated filer, Smaller reporting company³
Legal formCorporation²
LEI5493002JYRNNJ4UY7Q16²
StatusActive²
LEI statusLapsed (not renewed)²
Registered addressC/O LEGALINC CORPORATE SERVICES INC., 19713 Newark, United States²
Registered withDivision of Corporations, Department of State, 2017660²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2019

-62.3%Gross margin⁴

-4490.5%Operating margin⁴

-4753.2%Net margin⁴

231.6%Revenue growth, 2019⁴

Where the money goes

Where each dollar of revenue went, fiscal 2019

Cost of revenueInterest

Cost of revenue37¢$409.0K
Interest63¢$682.0K

Out of $252.0K in revenue.⁴⁵ The company lost money this year.

Financial statements

Revenue⁵⁴$252.0K in 2019+232% since 2018

Gross profit⁵⁴-$157.0K in 2019−25% since 2018

Operating income⁶⁷⁵⁴-$11.3M in 2019+1393% since 2016

Net income⁶⁷⁵⁴-$12.0M in 2019+1331% since 2016

Fiscal year	2016	2017	2018	2019
Revenue			$76.0K⁵	$252.0K⁴
Cost of revenue			$284.0K⁵	$409.0K⁴
Gross profit			-$208.0K⁵	-$157.0K⁴
Research and development	$132.5K⁶	$907.5K⁷	$241.0K⁵	$0⁵
Operating expenses
Operating income	-$757.7K⁶	-$6.1M⁷	-$15.8M⁵	-$11.3M⁴
Interest				$682.0K⁵
Income before tax
Income tax	$800⁶	$800⁷	$0⁵	$0⁵
Net income	-$837.1K⁶	-$6.2M⁷	-$16.8M⁵	-$12.0M⁴
Earnings per share			-$1.64⁵	-$1.24⁵
Earnings per share (diluted)
Shares (weighted, basic)

Total assets⁶⁷⁵⁴$420.0K in 2019−93% since 2016

Shareholders’ equity⁷⁵⁴¹¹-$9.9M in 2019

Cash⁴$50.0K in 2019−99% since 2018

Fiscal year	2016	2017	2018	2019
Cash			$3.9M⁴	$50.0K⁴
Current assets	$316.5K⁶	$124.9K⁷	$4.7M⁵	$420.0K⁴
Total assets	$6.2M⁶	$6.2M⁷	$5.1M⁵	$420.0K⁴
Accounts payable
Current liabilities	$3.0M⁶	$5.7M⁷	$2.2M⁵	$10.3M⁴
Total liabilities	$3.0M¹⁰
Retained earnings
Shareholders’ equity	$3.2M⁷	$448.0K⁵	$2.9M⁴	-$9.9M¹¹
Shares outstanding	9.0M shares⁶	10.5M shares⁷	10.8M shares⁵	10.9M shares⁴

Cash from operations⁶⁷⁵⁴-$8.7M in 2019+1573% since 2016

Share buybacks⁵$0 in 2019

Fiscal year	2016	2017	2018	2019
Cash from operations	-$522.3K⁶	-$1.3M⁷	-$9.6M⁵	-$8.7M⁴
Share buybacks			$250.0K⁵	$0⁵
Cash from financing

Compare Adhera Therapeutics, Inc. with another company

What it owns

What Adhera Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

Item	Latest	A year before	Change
Cash and cash equivalents	$32.0K¹² Dec 31, 2022	$76.0K¹¹ Dec 31, 2021	−57.9%

Leadership

Who has led Adhera Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

Chair

President

Chief financial officer

Chief operating officer

Mihir Munsif2017

2010201520202025

Chief executive officerAndrew Albert Kucharchuk Jul 20, 2020 to Jul 20, 2020¹³
Chief executive officerNancy R. Phelan Apr 4, 2019 to Apr 4, 2019¹⁴
Chief executive officerRobert Moscato Jr. Jun 25, 2018 to Jul 16, 2018¹⁵
Chief executive officerJoseph W. Ramelli Nov 17, 2016 to Apr 7, 2017¹⁶
Chief executive officerJ. Michael French Jun 23, 2008 to Jan 2, 2015¹⁷
Chief executive officerSteven C. Quay Jan 3, 2006 to Apr 2, 2008¹⁸
ChairVuong Trieu Nov 22, 2016 to Apr 18, 2018¹⁹
ChairSteven C. Quay Jan 3, 2006 to Jun 12, 2008¹⁸
PresidentJ. Michael French May 21, 2009 to Jan 2, 2015²⁰
PresidentGordon Brandt Dec 20, 2007 to Apr 2, 2008²¹
PresidentSteven C. Quay Jan 3, 2006 to Sep 28, 2007¹⁸
Chief financial officerRobert Eric Teague Sep 26, 2018 to Jan 17, 2019²²
Chief financial officerDaniel E. Geffken Jun 2, 2014 to Jun 2, 2014²³
Chief financial officerPeter S. Garcia Jul 15, 2009 to Aug 29, 2011²⁴
Chief financial officerBruce R. York Feb 19, 2008 to May 21, 2009²⁵
Chief financial officerPhilip C. Ranker Jan 4, 2006 to Jan 6, 2014²⁶
Chief operating officerMihir Munsif Feb 14, 2017 to Feb 14, 2017²⁷

Board members and other officers (46)

SVP Finance & AccountingRhonda L. Stanley Nov 4, 2019 to Nov 5, 2019²⁸
Chief Scientific OfficerLarn Hwang Feb 14, 2017 to Apr 18, 2018²⁹
Chief Commercial OfficerErik Emerson Jun 27, 2017 to Jul 12, 2018³⁰
Executive V.P. R&DRichard Theodore Ho Sep 7, 2011 to Jan 6, 2014³¹
Chief Scientific OfficerBarry Polisky Jan 5, 2009 to Aug 29, 2011³²
Chief Actg Officer, Asst Sec.Bruce R. York Jul 3, 2007 to Dec 7, 2007³³
Chief Scientific OfficerHenry R. Costantino Oct 9, 2007 to Aug 5, 2008³⁴
Sr VP, Operations & MfgDavid E. Wormuth Jan 25, 2006 to May 29, 2007³⁵
Exec VP of Science and ClinicaGordon Brandt Jan 25, 2006 to Apr 24, 2007³⁶
Exec. VP of Business DevpTimothy M. Duffy Feb 3, 2006 to Jul 2, 2008³⁷
Board memberTrond Kydd Waerness Apr 21, 2022 to Apr 21, 2022³⁸
Board memberCharles L. Rice Jr. Apr 28, 2022 to Apr 28, 2022³⁹
Board memberZahed Subhan Nov 29, 2021 to Nov 29, 2021⁴⁰
Board memberAndrew Albert Kucharchuk Jul 20, 2020 to Jul 20, 2020¹³
Board memberTimothy Boris May 7, 2018 to May 7, 2018⁴¹
Board memberUli Hacksell Jul 2, 2018 to Jul 11, 2018⁴²
Board memberRobert Moscato Jr. Jul 11, 2018 to Jul 16, 2018⁴³
Board memberErik Emerson Jul 12, 2018 to Jul 12, 2018⁴⁴
Board memberVuong Trieu Oct 4, 2018 to Oct 4, 2018⁴⁵
Board memberNancy R. Phelan Oct 24, 2018 to Apr 4, 2019⁴⁶
Board memberPhilippe Calais Jan 4, 2017 to Jan 3, 2018⁴⁷
Board memberIsaac Blech Nov 27, 2017 to Apr 18, 2018⁴⁸
Board memberPhilip C. Ranker Jan 6, 2014 to Apr 18, 2018⁴⁹
Board memberJoseph W. Ramelli Oct 10, 2012 to Nov 17, 2016⁵⁰
Board memberStefan Loren Oct 10, 2012 to Jan 4, 2017⁵¹
Board memberR. John Fletcher Jul 18, 2011 to Sep 7, 2011⁵²
Board memberChiang J. Li Jul 23, 2010 to Jul 23, 2010⁵³
Board memberMichael Douglas Taylor Jul 23, 2010 to Sep 7, 2011⁵⁴
Board memberPeter Parker Jul 23, 2010 to Sep 7, 2011⁵⁵
Board memberJ. Michael French Oct 15, 2010 to Jan 2, 2015⁵⁶
Board memberSteven C. Quay Mar 20, 2009 to Mar 20, 2009⁵⁷
Board memberJames Karis Aug 11, 2009 to Sep 7, 2011⁵⁸
Board memberGregory Sessler Jun 10, 2008 to Sep 7, 2011⁵⁹
Board memberJames Rothman Jun 10, 2008 to May 21, 2009⁶⁰
Board memberDaniel Peters Jun 12, 2008 to May 21, 2009⁶¹
Board memberDevin Wenig Jan 4, 2006 to Nov 2, 2007⁶²
Board memberLeslie D. Michelson Mar 23, 2006 to Jun 15, 2007⁶³
Board memberJohn Pollock V. Mar 29, 2006 to Jun 12, 2008⁶⁴
Board memberGerald T. Stanewick Apr 7, 2006 to May 12, 2008⁶⁵
Board memberBruce R/fa Thaw Jun 7, 2006 to May 21, 2009⁶⁶
Board memberAlexander D. Cross Jun 15, 2006 to Jun 12, 2008⁶⁷
Board memberIan R. Ferrier Jun 15, 2006 to Jun 15, 2007⁶⁸
Board memberJ. Carter Beese Jr. Jun 15, 2006 to Mar 12, 2007⁶⁹
Board memberMyron Z. Holubiak Jun 15, 2006 to Aug 16, 2007⁷⁰
Board memberSusan B. Bayh Jun 15, 2006 to Jun 12, 2008⁷¹
General counselPeter D. Weinstein Oct 24, 2017 to Oct 24, 2017⁷²

Former names

Marina Biotech, Inc.Jun 28, 2010 to Oct 9, 2018³
MDRNA, Inc.Jun 10, 2008 to Jul 21, 2010³
NASTECH PHARMACEUTICAL CO INCOct 16, 1995 to Jun 9, 2008³

Timeline

Jan 18, 20248-K Ended a material agreement⁷³
Jan 16, 20248-K Executive or director change⁷⁴
Nov 29, 20238-K Entered a material agreement⁷⁵
Oct 12, 20238-K Regulation FD disclosure⁷⁶
Jun 29, 20238-K Entered a material agreement; Unregistered sale of shares⁷⁷
May 5, 20238-K Entered a material agreement; Unregistered sale of shares⁷⁸
May 4, 20238-K Entered a material agreement; Unregistered sale of shares⁷⁹
Mar 8, 20238-K Entered a material agreement; Unregistered sale of shares⁸⁰
Feb 23, 20238-K Entered a material agreement; Unregistered sale of shares⁸¹
Jan 26, 20238-K Entered a material agreement; Unregistered sale of shares⁸²
Nov 22, 20228-K Entered a material agreement; New debt or obligation; Unregistered sale of shares⁸³
Nov 9, 20228-K Executive or director change⁸⁴
Jul 20, 2020New chief executive Andrew Albert Kucharchuk becomes CEO¹³
Apr 4, 2019New chief executive Nancy R. Phelan becomes CEO¹⁴
Jun 25, 2018New chief executive Robert Moscato Jr. becomes CEO¹⁵
Nov 17, 2016New chief executive Joseph W. Ramelli becomes CEO¹⁶
Jun 23, 2008New chief executive J. Michael French becomes CEO¹⁷
Jan 3, 2006New chief executive Steven C. Quay becomes CEO¹⁸
Sep 23, 1983Founded Adhera Therapeutics, Inc. is founded²

Filings

44 filings to the SEC since October 2021: 4 annual reports, 7 quarterly reports, 19 major events, 3 insider forms, 11 other. The latest 20:

Jan 30, 2024SEC STAFF ACTION EDGAR
Jan 18, 20248-K EDGAR
Jan 16, 20248-K EDGAR
Nov 29, 20238-K EDGAR
Nov 20, 202310-Q EDGAR
Nov 15, 2023NT 10-Q EDGAR
Oct 12, 20238-K EDGAR
Aug 21, 202310-Q EDGAR
Aug 15, 2023NT 10-Q EDGAR
Jun 29, 20238-K EDGAR
May 22, 202310-Q EDGAR
May 15, 2023NT 10-Q EDGAR
May 5, 20238-K EDGAR
May 4, 20238-K EDGAR
May 2, 202310-K/A EDGAR
Mar 31, 202310-K EDGAR
Mar 8, 20238-K EDGAR
Feb 23, 20238-K EDGAR
Jan 26, 20238-K EDGAR
Dec 2, 2022S-1 EDGAR

The 44 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

SEC filer profile

How Adhera Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

Name on EDGARAdhera Therapeutics, Inc.¹
CIK0000737207
Employer ID (EIN)11-2658569¹
Filer statusNon-accelerated filer<br>smaller reporting company¹
Incorporated inDelaware¹
Fiscal year endsDecember 31¹
Industry code (SIC)2834 Pharmaceutical Preparations¹
SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
Business addressP.O. Box 2161, Wake Forest, NC 27588¹
Phone919-578-5901¹
Shares outstanding7,220,900 as of Nov 20, 2023⁹
Public float$3.1M as of Jun 30, 2022⁸⁵
On EDGAR sinceOct 16, 1995¹
Filings1,210 in all: 4 (369), 8-K (279), 10-Q (81), 3 (50), CORRESP (32), SC 13G/A (30), UPLOAD (29), SC 13G (22)¹
All 56 form types
10-K (21), DEF 14A (19), EFFECT (18), 4/A (16), 424B5 (15), S-3 (15), S-8 (15), NT 10-Q (14), 8-K/A (12), PRE 14A (12), S-1/A (12), 424B3 (11), D (11), POS AM (11), DEFA14A (9), S-1 (9), SC 13D/A (9), ARS (8), CT ORDER (8), NT 10-K (7), 10-K405 (6), 10-K/A (5), S-3/A (5), 10-Q/A (4), 10QSB (4), S-2/A (4), SC 13D (4), DEFR14A (3), PRER14A (3), RW (3), SC TO-I/A (3), 424B2 (2), 424B4 (2), S-2 (2), S-3MEF (2), SC TO-I (2), 10-K405/A (1), 10KSB40 (1), 25-NSE (1), 3/A (1), 425 (1), 5 (1), 5/A (1), 8-A12G (1), DEFM14A (1), PREM14A (1), REGDEX (1), SEC STAFF ACTION (1)
Latest filingsAnnual report (10-K) Mar 31, 2023
Quarterly report (10-Q) Nov 20, 2023
Proxy statement (DEF 14A) Jun 27, 2022
Latest 8-K (8-K) Jan 18, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARAdhera Therapeutics, Inc. filings on SEC EDGAR
2
GLEIFAdhera Therapeutics, Inc. LEI record (5493002JYRNNJ4UY7Q16)
3
SEC EDGARAdhera Therapeutics, Inc. filings on SEC EDGAR
4
SEC EDGARAdhera Therapeutics, Inc. 10-K for fiscal 2019
5
SEC EDGARAdhera Therapeutics, Inc. 10-K for fiscal 2019
6
SEC EDGARAdhera Therapeutics, Inc. 10-K for fiscal 2016
7
SEC EDGARAdhera Therapeutics, Inc. 10-K for fiscal 2017
8
SEC EDGARAdhera Therapeutics, Inc. 10-Q for fiscal 2023
9
SEC EDGARAdhera Therapeutics, Inc. 10-Q for fiscal 2023
10
SEC EDGARAdhera Therapeutics, Inc. 10-K for fiscal 2016
11
SEC EDGARAdhera Therapeutics, Inc. 10-K for fiscal 2019
12
SEC EDGARAdhera Therapeutics, Inc. 10-K for fiscal 2022
13
SEC EDGARAndrew Albert Kucharchuk, Chief executive officer
14
SEC EDGARNancy R. Phelan, Chief executive officer
15
SEC EDGARRobert Moscato Jr., Chief executive officer
16
SEC EDGARJoseph W. Ramelli, Chief executive officer
17
SEC EDGARJ. Michael French, Chief executive officer
18
SEC EDGARSteven C. Quay, Chief executive officer
19
SEC EDGARVuong Trieu, Chair
20
SEC EDGARJ. Michael French, President
21
SEC EDGARGordon Brandt, President
22
SEC EDGARRobert Eric Teague, Chief financial officer
23
SEC EDGARDaniel E. Geffken, Chief financial officer
24
SEC EDGARPeter S. Garcia, Chief financial officer
25
SEC EDGARBruce R. York, Chief financial officer
26
SEC EDGARPhilip C. Ranker, Chief financial officer
27
SEC EDGARMihir Munsif, Chief operating officer
28
SEC EDGARRhonda L. Stanley, SVP Finance & Accounting
29
SEC EDGARLarn Hwang, Chief Scientific Officer
30
SEC EDGARErik Emerson, Chief Commercial Officer
31
SEC EDGARRichard Theodore Ho, Executive V.P. R&D
32
SEC EDGARBarry Polisky, Chief Scientific Officer
33
SEC EDGARBruce R. York, Chief Actg Officer, Asst Sec.
34
SEC EDGARHenry R. Costantino, Chief Scientific Officer
35
SEC EDGARDavid E. Wormuth, Sr VP, Operations & Mfg
36
SEC EDGARGordon Brandt, Exec VP of Science and Clinica
37
SEC EDGARTimothy M. Duffy, Exec. VP of Business Devp
38
SEC EDGARTrond Kydd Waerness, Board member
39
SEC EDGARCharles L. Rice Jr., Board member
40
SEC EDGARZahed Subhan, Board member
41
SEC EDGARTimothy Boris, Board member
42
SEC EDGARUli Hacksell, Board member
43
SEC EDGARRobert Moscato Jr., Board member
44
SEC EDGARErik Emerson, Board member
45
SEC EDGARVuong Trieu, Board member
46
SEC EDGARNancy R. Phelan, Board member
47
SEC EDGARPhilippe Calais, Board member
48
SEC EDGARIsaac Blech, Board member
49
SEC EDGARPhilip C. Ranker, Board member
50
SEC EDGARJoseph W. Ramelli, Board member
51
SEC EDGARStefan Loren, Board member
52
SEC EDGARR. John Fletcher, Board member
53
SEC EDGARChiang J. Li, Board member
54
SEC EDGARMichael Douglas Taylor, Board member
55
SEC EDGARPeter Parker, Board member
56
SEC EDGARJ. Michael French, Board member
57
SEC EDGARSteven C. Quay, Board member
58
SEC EDGARJames Karis, Board member
59
SEC EDGARGregory Sessler, Board member
60
SEC EDGARJames Rothman, Board member
61
SEC EDGARDaniel Peters, Board member
62
SEC EDGARDevin Wenig, Board member
63
SEC EDGARLeslie D. Michelson, Board member
64
SEC EDGARJohn Pollock V., Board member
65
SEC EDGARGerald T. Stanewick, Board member
66
SEC EDGARBruce R/fa Thaw, Board member
67
SEC EDGARAlexander D. Cross, Board member
68
SEC EDGARIan R. Ferrier, Board member
69
SEC EDGARJ. Carter Beese Jr., Board member
70
SEC EDGARMyron Z. Holubiak, Board member
71
SEC EDGARSusan B. Bayh, Board member
72
SEC EDGARPeter D. Weinstein, General counsel
73
SEC EDGAREnded a material agreement
74
SEC EDGARExecutive or director change
75
SEC EDGAREntered a material agreement
76
SEC EDGARRegulation FD disclosure
77
SEC EDGAREntered a material agreement; Unregistered sale of shares
78
SEC EDGAREntered a material agreement; Unregistered sale of shares
79
SEC EDGAREntered a material agreement; Unregistered sale of shares
80
SEC EDGAREntered a material agreement; Unregistered sale of shares
81
SEC EDGAREntered a material agreement; Unregistered sale of shares
82
SEC EDGAREntered a material agreement; Unregistered sale of shares
83
SEC EDGAREntered a material agreement; New debt or obligation; Unregistered sale of shares
84
SEC EDGARExecutive or director change
85
SEC EDGARAdhera Therapeutics, Inc. 10-K/A filed May 2, 2023: public float